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doi:10.1016/j.kjms.2012.02.008Abstract Brown tumor is a rare late-stage skeletal change caused by long-term stimulation of
excess parathyroid hormone. It is not neoplastic, but a reparative cellular process. Common
sites of brown tumor are the ribs, clavicle, long bones and pelvic girdle. Solitary maxillary
brown tumor as initial presentation of primary hyperparathyroidism is rare; it is often accom-
panied by brown tumors of the other facial bones. Here, we present the first case of solitary
maxillary brown tumor in a 29-year-old ethnic Chinese woman with initial presentation of
a large tumor filling the left maxillary sinus. Underlying long-standing primary hyperparathy-
roidism caused by a large parathyroid adenoma was finally diagnosed. Brown tumor tends to
be misdiagnosed as malignancy, and delayed diagnosis of the underlying hyperparathyroidism
is common. Our case validates the suggestion that young women have a higher probability of
brown tumor. Biopsy of the suspicious bone tumor and blood tests for calcium and parathyroid
hormone level are crucial and essential to reach the correct diagnosis. Most brown tumors
show spontaneous regression after parathyroidectomy. However, direct excision of the brown
tumor may be indicated to avoid the risk of facial deformity and orbital compression at
a special anatomical site, as in our case.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Brown tumor, also called osteitis fibrosa cystica, is an
unusual skeletal change with involvement in <2% of casesEndocrinology and Metabo-
Nan-Hsiao Street, Changhua
(S.-T. Tu).
vier Taiwan LLC. All rights reservof primary hyperparathyroidism [1e3]. Brown tumor is not
neoplastic, but a reparative cellular process. Long-term
increased secretion of parathyroid hormone (PTH) enhances
bone mobilization through rapid osteoclast turnover and
contributes to the formation of brown tumors. In regions
where bone loss is rapid, hemorrhage, hemosiderin deposi-
tion, and vascularized fibrous tissue replace the normal bone
contents, resulting in a reddish-brown appearance [2].
Common sites of brown tumor are the ribs, clavicle, tibia,ed.
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presentation of primary hyperparathyroidism is rare; it is
often accompanied by brown tumors of the mandible, palate
or the other facial bone [4e7].
We present the case of a 29-year-old woman with left
facial pain caused by left maxillary brown tumor, which was
not diagnosed as being related to hyperparathyroidism until
surgical removal of the tumor. To the best of our knowl-
edge, this is the first report of solitary maxillary brown
tumor as initial presentation of parathyroid adenoma in an
ethnic Chinese patient. We also summarize several critical
clinical points that are easily missed and should be kept in
mind.Case presentation
A 29-year-old woman visited our neurology clinic with the
odd sensation of progressive swelling and pain in the left
side of the face, even when washing the face, during the
past 3 months. She felt left eye pain when opening the eye.
She had no diplopia or blurred vision. Her menstruation
was normal and regular. She had had urinary stones and
a depressed mood treated by specialists in recent years.
She denied a history of trauma to this area, dental problems,
or use of drugs. Physical examination revealed tenderness
in the left side of the face, near the cranial nerve V-1 and
V-2 dermatome area, without motor impairment. She had
normal pupil function, eyeball movements and visual fieldFigure 1. (A) Coronal plain T1-weighted magnetic resonance ima
the left maxillary sinus, with bony expansion and remolding. (B) Cor
image revealed strong enhancement (arrow). (C,D) T2-weighted ma
(small arrows) probably due to the cystic contents of the brown tuwithout ptosis or proptosis. Her facial appearance was also
normal without asymmetry.
Brain magnetic resonance imaging demonstrated a well-
circumscribed largemassmeasuring 37mm43mm43mm
in the left maxillary sinus, with bony expansion and
remolding (Fig. 1). The normal residual sinus was severely
displaced inferiorly. The left inferior rectus muscle was
compressed inferiorly, and the left nasal cavity was obliter-
ated. She underwent a diagnostic biopsy that revealed
a tumor characterized by the presence of many multinucle-
ated giant cells with cellular vascular stroma, which sug-
gested central giant cell granuloma, cherubism, or giant cell
tumor of the bone.
Blood biochemistry showed an elevated calcium level of
15.9 mg/dL (reference range, 8.7-10.0 mg/dL) and a low
normal phosphorus level of 2.6 mg/dL (reference range,
2.5e4.5 mg/dL). The serum alkaline phosphatase level was
712 IU/L (reference range, 36e108 IU/L). Subsequent
testing revealed normal renal function tests and a high
intact PTH level of 1846 pg/mL (reference range, 12e65 pg/
mL), confirming primary hyperparathyroidism. Both kid-
neyeureterebladder (KUB) and renal ultrasonography
revealed bilateral medullary nephrocalcinosis. Plain radi-
ography of the skull showed a mottled appearance of the
calvarium, presenting the characteristic salt-and-pepper
pattern of hyperparathyroidism. Ultrasonography of the
neck and a parathyroid scan (Tc99 m sestamibi) showed
a 35 mm  12 mm  11 mm solitary mass at the left lower
thyroid bed, consistent with a parathyroid tumor. She deniedging demonstrated a well-circumscribed large mass (arrow) in
onal contrast enhancement with fat saturation on T1-weighted
gnetic resonance imaging showed multiple hyperintense lesions
mor.
402 H.-K. Sia et al.a family history of hyperparathyroidism or other endocrine
disorder. A screen for multiple endocrine neoplasm types
1 and 2A was performed, including serum prolactin, insulin-
like growth factor-1, 24-hour urine vanillylmandelic acid and
free cortisol levels, which were all within normal limits.
In consideration of the patient’s risk of facial deformity
and damage to vision and eye ball movements, surgical
decompression was suggested. After endovascular devas-
cularization by an angiographic embolization procedure,
surgical removal of the hypervascular tumor was performed
smoothly by functional endoscopic sinus surgery. Grossly,
the tumor was brownish and elastic to firm in texture.
Histopathological examination showed giant cell granuloma
consisting of granuloma-like aggregates of histiocytes with
associated clumps of hemosiderin in the fibroblastic stroma.
Parathyroidectomy was performed, showing a left lower
parathyroid tumor that weighed 2.0 g. Histopathological
examination of the mass showed an adenoma composed
predominantly of chief cells with a glandular pattern in
places. One week later, the PTH level was 77 pg/mL and the
calcium level was 8.5 mg/dL. Two months after surgery, the
PTH level had increased to 360 pg/mL, the calcium level
was 8.9 mg/dL, phosphorus was 2.4 mg/dL, and the alkaline
phosphatase level had decreased to 434 IU/L. A Tc99 m
methylene diphosphonate bone scan showed increased
uptake in the anterolateral right eighth rib, lateral right sixth
and ninth ribs, bilateral sternoclavicular joints, left humeral
head, and left femoral head, which suggested fractures,
pseudofractures or brown tumors. The patient was free
of symptoms and living well. At 4 months after para-
thyroidectomy, she still had a persistently elevated PTH level
of 383 pg/mL, with low blood calcium of 8.1 mg/dL, phos-
phorus of 2.5 mg/dL, and alkaline phosphatase of 285 IU/L.
We arranged follow-up ultrasonography of the neck, which
revealed no local recurrence of the parathyroid tumor.Discussion
Brown tumor is caused by hyperparathyroidism, which may
be primary, secondary or tertiary. The major determinant
may be the chronicity of excess secretion of and stimula-
tion by PTH, rather than the PTH level per se. Screening for
hypercalcemia can lead to early treatment of hyperpara-
thyroidism and prevent the development of advanced bony
complications. The combination of vitamin D deficiency
and primary hyperparathyroidism predisposes patients to
develop the classic skeletal changes of primary hyper-
parathyroidism [6,8].
Primary hyperparathyroidism affects women more than
men by almost 3:1. It can occur at any age, but the majority
of cases are postmenopausal women [8]. Our patient was
much younger than average, which supports the findings of
Al-Gahtany et al., who reviewed 16 cases involving brown
tumors of the skull base, and revealed that the mean age of
the patients was 32 years, and that 75% of them were
women [2]. Resendiz-Colosia et al. have reported a series
of 22 cases of maxillofacial brown tumor, showing that 91%
of them were women [6]. A possible explanation is that
young women have greater susceptibility for PTH and
a predisposition to brown tumors. The exact causes remain
to be determined.Brown tumor is just a reaction rather than a true tumor,
but it may be recognized as a primary bone tumor and be
excised, as in our case. It has also been mistaken for bone
metastases, especially when X-ray films show multiple
osteolytic bone lesions [6,9,10]. Although surgical resection
may not be necessary, biopsy of the tumor is a crucial and
essential step to exclude malignancy and other bone
disease, and it helps in avoiding unnecessary extensive
operation [2,3]. The differential diagnosis should include
giant-cell tumor of the bone, giant-cell reparative granu-
loma, aneurismal bone cyst, and osteosarcoma [11].
Pathology cannot distinguish giant cell tumor of the bone
from the brown tumor of hyperparathyroidism. However,
they can be easily differentiated on the basis of laboratory
findings. Blood calcium and PTH levels should both be
checked, because a primary hyperparathyroid patient may
have a normal blood calcium level due to many factors, such
as vitamin D deficiency [3,12]. A higher than expected PTH
level with a normal to high blood calcium level is diagnostic
for brown tumor caused by primary hyperparathyroidism.
If early diagnosis and treatment of hyperparathyroidism
are undertaken, the prognosis is excellent in most patients.
Resendiz-Colosia et al. have shown that all of their 20 cases
of maxillofacial brown tumor that were followed up for 2
years had spontaneous regression after parathyroidectomy.
In 90% of the cases, regression was clinically complete and
mostly within 4e20 months [6]. Regression in those aged
>60 years and with bone lesions located in cancellous bone
may take longer, which may reflect differences in the rate
of bone turnover [5e7,13]. The first choice in managing
brown tumor caused by primary hyperparathyroidism is
parathyroidectomy. Most of the bone lesions will regress
with time after parathyroidectomy, thus, surgical removal
of the brown tumor may not be necessary [2e5]. However,
at least two studies have shown that the tumors failed to
regress and became even larger after parathyroidectomy.
One patient had extensive cystic changes with attendant
destruction, and the tissue damage was too great to
remodel [4]. The other patient had no conclusive cause,
although she was 72 years old [14]. In such cases in which
resolution is slow or growth continues, excision of the
brown tumor should be performed [5].
In some critical conditions or special anatomical sites,
especially the skull base, many patients have been treated
with surgical excision of the tumor to avoid facial defor-
mation or damage to vital structures, such as compression
of the nerves or eyeball, as in our case [2,15]. The patient’s
willingness for a quick resolution of symptoms should also
be taken into account. Different management strategies
should be used with different bone lesions and different
patients [5e7,15,16].
The pathological conditions in primary hyperparathy-
roidism are more complicated than those in the secondary
and tertiary types. Primary hyperparathyroidism is mostly
caused by adenoma (>80%), followed by hyperplasia, and
carcinoma in fewer than 0.5e4% of patients [5,8,17].
However, Resendiz-Colosia et al. have reported a much
higher percentage (13.6%) of carcinoma in their 22 patients
with maxillofacial brown tumors [6]. Another case review
of orbital brown tumors has shown a similar result [18].
This serves to remind us that a suspicious case should
undergo long-term follow-up to rule out malignancy.
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but should also be considered, including multiple endo-
crine neoplasia type 1 or 2A syndromes, familial isolated
hyperparathyroidism, and hyperparathyroidismejaw tumor
syndrome [5,19].
In our case, the patient’s PTH level decreased to 77 pg/mL
1 week postoperatively, but increased again to 383 pg/mL
4 months after surgery. Does this mean a recurrence? Mit-
tendorf et al. have suggested that it is a compensatory
response to remineralization of cortical bone. They have
demonstrated that persistently elevated PTH levels occurred
in 27% of patients following curative parathyroidectomy. The
elevation in postoperative PTH levels was usually transient
and resolved within 5 months of surgery [20]. Carty et al.
have suggested adequate calcium and vitamin D supplements
appear to prevent or normalize the condition [21]. In our
case, with an elevated PTH level accompanied with a low
blood calcium level, a compensatory response may be
a reasonable explanation.
In conclusion, we present a case of maxillary brown
tumor in a young woman whose long-standing symptomatic
hyperparathyroidism had not been recognized in time.
Brown tumor tends to be misdiagnosed as malignancy and
delayed diagnosis of underlying hyperparathyroidism is
common. A young woman may have a higher probability of
brown tumor. We have summarized several critical clinical
points in managing brown tumor. A biopsy of the suspicious
bone tumor and blood tests for calcium and PTH levels are
crucial and essential to reach the correct diagnosis. Direct
excision of the brown tumor may be indicated in special
anatomical sites, as in our case. A much higher percentage
of maxillofacial brown tumors tend to be caused by para-
thyroid carcinoma, which should always be kept in mind in
spite of a benign histopathological report.References
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